TSN1611

· Tyligand Pharmaceuticals (Suzhou) Limited

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TSN1611, covering 2026-04-24 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation [Phase 1, Phase 2]